Search clinical trials for: Mosunetuzumab Lenalidomide

Total 1074 results

Dana-Farber Cancer Institute
Novartis; Brigham and Women's Hospital

Terminated

RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer

Head and Neck Cancer

United States
University of Bologna

Terminated

Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients

Peripheral T-cell Lymphoma

Italy
Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (HOVON174MM)

Multiple Myeloma
Attaya Suvannasankha
Janssen Scientific Affairs, LLC; Indiana Institute for Medical Research

Withdrawn

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

Multiple Myeloma

United States
University of Alabama at Birmingham

Recruiting

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Multiple Myeloma

United States
University Hospital, Toulouse
Celgene; Onyx Therapeutics, Inc.

Unknown

Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction (IFM-CRd)

Multiple Myeloma

France
University of Pennsylvania

Completed

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
JW Pharmaceutical

Completed

Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients

Multiple Myeloma

Korea, Republic of, United States
New Mexico Cancer Care Alliance
Celgene Corporation

Terminated

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer | Epithelial Ovarian Cancer | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
PETHEMA Foundation
Celgene Corporation

Completed

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (QUIREDEX)

Multiple Myeloma

Spain
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (CONFIRM)

Multiple Myeloma in Relapse

France
University of Illinois at Chicago

Recruiting

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma (HEME-18)

Multiple Myeloma

United States
Celgene

Terminated

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma (EXPECT)

T-cell Non-Hodgkin's Lymphoma

France, United States, Australia, Belgium
Sidney Kimmel Comprehensive Cancer Center at Johns...
Celgene Corporation

Completed

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

Prostate Cancer

United States
Jun Zhang
Baylor College of Medicine; Celgene Corporation

Terminated

Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Beth Israel Deaconess Medical Center

Terminated

Lenalidomide After Allo Transplant

Lymphoma | Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

Melanoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Celgene Corporation

Terminated

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Myelodysplastic Syndrome | MDS | Low to Intermediate-1 MDS | Non-deletion 5q

United States
Washington University School of Medicine

Completed

Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Myelodysplastic Syndromes

United States
Celgene

Recruiting

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

Spain, Italy, Germany, Austria, France, Greece, Netherlands
Celgene

Completed

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Leukemia Lymphocytic Chronic B-Cell

United States, Austria
Celgene

Completed

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

Healthy Volunteers

United States
Celgene Corporation
Prologue Research International

Completed

A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Wake Forest University Health Sciences
Celgene; Amgen; Janssen, LP

Active, not recruiting

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Bristol-Myers Squibb

No longer available

Expanded Access Treatment Protocol CA204-143

Multiple Myeloma

United States
Cancer Trials Ireland

Completed

Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Ireland
Mingzhi Zhang

Unknown

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
Georgetown University
Celgene Corporation; Cephalon

Completed

Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) (Phase I BLR)

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC

Completed

Short Course Daratumumab in Patients With Multiple Myeloma

Multiple Myeloma

United States
Ruijin Hospital

Unknown

Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Non-hodgkin Lymphoma,B Cell

China
Celgene

Terminated

A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). (RENEW)

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

United States, Spain, United Kingdom, Germany, France, Czechia, Israel, Italy, Poland, Portugal, Puerto Rico, Russian Federation
Celgene

Completed

Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

Myelodysplastic Syndromes

Japan
Celgene

Completed

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
University Hospital, Bordeaux

Completed

Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma (REV-LEG)

Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)

France
Celgene Corporation

Completed

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene Corporation

Completed

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Melanoma | Neoplasm Metastasis

United States, Canada
Anaveon AG

Terminated

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Hematologic Diseases | Multiple Myeloma | Refractory Multiple Myeloma | Adult Disease | Relapsed Cancer

Spain, Germany, France, Denmark, Switzerland
Sanofi

Completed

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

Plasma Cell Myeloma

United States
Fondazione Italiana Linfomi ONLUS

Completed

A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Diffuse Large B-cells Non-Hodgkin Lymphoma

Italy
AbbVie
Genentech, Inc.; Celgene Corporation

Withdrawn

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Multiple Myeloma

United States, Australia, Canada, Spain
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

Intraocular Melanoma | Malignant Conjunctival Neoplasm

United States
Emory University
Celgene Corporation

Terminated

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic

United States
Auxilio Mutuo Cancer Center

Unknown

Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

Lymphoma

Puerto Rico
University of Washington
Genentech, Inc.

Recruiting

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone...

United States
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

B-cell Chronic Lymphocytic Leukemia

United States, Spain, United Kingdom, Canada, Belgium, Czechia, Hungary, Italy, Poland, Israel, Germany, Ireland, France, New Zealand, Denmark, Australia, Netherlands, Romania, Russian Federation, Sweden, Austria, South Africa, Colo... and more
The Lymphoma Academic Research Organisation

Completed

Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP (REMARC)

Lymphoma | Diffuse Large B-cell Lymphoma

Belgium, Switzerland, France, Australia, Spain, Israel, Austria, Portugal, Poland
Celgene Corporation

Completed

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

Crohn's Disease

France, United States, United Kingdom, Israel
James Rubenstein
Incyte Corporation

Recruiting

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Primary Central Nervous System Lymphoma | CNS Lymphoma | Secondary Central Nervous System Lymphoma

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)

Multiple Myeloma

United States, Canada

Search clinical trials for: Mosunetuzumab Lenalidomide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations